METILPREDNISOLONE

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis1
53Sjogren syndrome1
56Behcet disease1
IDDisease name (Link within this page)Number of trials
63Idiopathic thrombocytopenic purpura1
300IgG4-related disease1

11. Myasthenia gravis


Clinical trials : 525 / Drugs : 355 - (DrugBank : 80) / Drug target genes : 75 - Drug target pathways : 139 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

53. Sjogren syndrome


Clinical trials : 448 / Drugs : 436 - (DrugBank : 104) / Drug target genes : 68 - Drug target pathways : 185 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

56. Behcet disease


Clinical trials : 110 / Drugs : 137 - (DrugBank : 40) / Drug target genes : 40 - Drug target pathways : 125 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 868 / Drugs : 544 - (DrugBank : 96) / Drug target genes : 82 - Drug target pathways : 195 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

300. IgG4-related disease


Clinical trials : 81 / Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 152 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries